IDELVION is indicated for the prophylaxis and treatment of bleeding in all patients with haemophilia B (congenital factor IX deficiency) including control and prevention of bleeding in surgical settings.5
Please refer to the SPC for full details on any special warnings and precautions for use.More Information
Efficacy as prophylaxis: Median AsBR* of zero.
The median AsBR for subjects that received the 7- or 14-day prophylactic treatment in the clinical trial was zero.2More Information
*See glossary of terms.
Dosing and administration
IDELVION is well tolerated.1-5
- IDELVION uses albumin fusion technology to extend half-life6
- Albumin has a well-established tolerability profile, a low potential for immunogenic reactions and well-known mechanism of clearance6
- One previously untreated patient (PUP) from the ongoing clinical trial developed a high titre inhibitor against FIX. There are insufficient data to provide information on inhibitor incidence in PUPs5
Please refer to the SPC for full details on adverse reactions, special warnings and precautions for use.More Information